Industries > Pharma > Atopic Dermatitis Drugs Market Forecast 2020-2030

Back to Pharma Reports

Atopic Dermatitis Drugs Market Forecast 2020-2030

Atopic Dermatitis Drugs Market Forecast 2020-2030: Forecasts and Analysis by Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report by Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics) and Geography with Profiles of Leading Companies

PAGES: 171

PRODUCT CODE: PHA0567

SUBMARKET: Drug Discovery Development & Production

DOWNLOAD FREE SAMPLE

Licence

Clear

DOWNLOAD FREE SAMPLE

SKU: PHA0567 Categories: Drug Discovery Development & Production, Pharma Tags: PHA0401, PHA0567

According to the report published by Visiongain, the Atopic Dermatitis Drugs market is projected at USD 5.5 billion in 2020. During the 2020-2030 prediction era, it is anticipated to grow at a CAGR of 6.6%. The most prevalent form of eczema is atopic dermatitis (AD), which affects a big proportion of the world’s population. While atopic dermatitis can happen at any era, the disease mostly impacts kids and babies, and subsides with era. Increasing AD incidence is the market’s main development stimulus.

The application of treatment guidelines for atopic dermatitis is difficult, partly because separate instruction papers are used by distinct organizations of experts and partly because the language of rules often represents the basis of proof rather than the practical “how to.” The Atopic Dermatitis Yardstick is component of a sequence established in reaction to the need to tackle it proactively. It provides a extensive overview on how the person with inadequately monitored or poorly regulated atopic dermatitis can perform a continuous step-up in treatment. Based on current guidelines and the combined clinical experience of the authors, patient profiles provide a practical and clinically meaningful guide to help physicians achieve the clear to near-clear goal of helping their patients.

The intention is not to substitute rules, but to supplement their suggestions integrating the recent studies and therapies, there is a need for a therapy system that all specialties can refer to, especially when it relates to how and when to speed up customer care. Based on present proof and clinical practice, the AD Yardstick offers a practical tool to assist realign therapy to the changing therapy paradigm, especially for clients who are not sensitive to present care norms. Which treatment to be used as maintenance therapy is a debate between nurses or caregivers and health care professionals, drawing into account patient age, previous treatment errors, lesion location, nurse and caregiver attitudes and environment, risk-benefit demographics, and price (insurer) factors.

Atopic dermatitis is a complicated disease triggered by various genetic and environmental factors interacting with each other. The impact is not only a itchy rash, but also the secondary impacts on the people psychological well-being and their carers, especially troubled sleep, especially in patients with serious disease. The purpose of this evaluation is to provide healthcare experts with a holistic strategy to managing atopic dermatitis that is difficult to treat, identified as atopic dermatitis that appears to be non-responsive to easy moisturizers and topical corticosteroids with moderate potency (categories VI and VII).

The critical significance of education and guidance is emphasized, as is the seminal function of secondary bacterial infection and polyclonal T-cell activation in nurses with serious, generalized illness triggering acute flares. Atopic dermatitis is a prevalent inflammatory skin disorder that generally impacts kids in atypical instances or those that do not react to therapy. It is a chronic disease that adversely impacts the standard of lives of nurses and their relatives, with phases of remission and flare-ups. An significant action for nurses with atopic dermatitis is aggressive emollient treatment. Patients should prevent the causes and allergens of personal diseases. Topical corticosteroids are the main therapy for flare-ups and are the norm relative to other therapies. Topical calcineurin inhibitors should not be used in children under two years of age or those who are immunosuppressed, and other individuals should be treated with secondline therapy. Rarely, the officer of the system.

Why you should buy Atopic Dermatitis Drugs Market Forecast 2020-2030: Forecasts and Analysis by Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics) and Geography, with Profiles of Leading Companies
What is the future of the Atopic Dermatitis Drugs market? Visiongain’s comprehensive analysis contains highly quantitative content delivering solid conclusions benefiting your analysis and illustrates new opportunities and potential revenue streams helping you to remain competitive. This definitive report will benefit your decision making and help to direct your future business strategy.

We guarantee in this 171 page report you will receive the following key information –

– View Atopic Dermatitis Drugs market forecasts and analysis from 2020-2030 to keep you ahead of your competitors and ensure you exploit key business opportunities
– The report provides detailed sales projections of the market, the competitors, and the commercial drivers and restraints allowing you to more effectively compete in the market. In addition to market forecasts from 2020-2030, our new study shows current market data, original critical analysis, and revealing insight into commercial developments
– Atopic Dermatitis Drugs revenue forecast
– Atopic Dermatitis Drugs connections forecast

– Examine 122 tables, charts, and graphs.
– Let our analysts present you with a thorough assessment of the current and future Atopic Dermatitis Drugs market prospects.
– This analysis will achieve quicker, easier understanding. Also you will gain from our analyst’s industry expertise allowing you to demonstrate your authority on the Atopic Dermatitis Drugs sector

– Discover sales predictions for the key end use submarkets from 2020-2030
– What are the dynamics of the Atopic Dermatitis Drugs industry? Which submarkets will generate the most revenue? Use our forecasts and expert insight to grow your business and give you more industry influence. Find where you can gain and how your organisation can succeed. Avoid falling behind. Stay informed about the potential for each of these Atopic Dermatitis Drugs submarkets with individual forecasts and analysis from 2020-2030.
– Drug Type submarket forecast 2020-2030
– Route of Administration submarket forecast 2020-2030
– End-Use submarket forecast 2020-2030

– Learn about the market prospects for the leading Atopic Dermatitis Drugs market segments 2020-2030
– How will various value chain members perform over the forecast period? Discover where the highest revenue potential lies from 2020-2030, learning about how Atopic Dermatitis Drugs revenue trickles down through the various market segments. These forecasts will also reveal the competitive landscape. You will see what is happening, explaining the challenges, trends, competitors, and market opportunities. Our report reveals forecasts for the 3 leading segmentations as follows.

– Drug Type Revenue Forecast 2020-2030
– Anti-inflammatory agents Market Forecast, 2020-2030
– Antihistamines Market Forecast, 2020-2030
– Immunosuppressant Market Forecast, 2020-2030
– Interleukin Inhibitors Market Forecast, 2020-2030
– Topical Phosphodiesterase (PDE-4) Market Forecast, 2020-2030
– Other Drug Type Market Forecast, 2020-2030

– Route of Administration Revenue Forecast 2020-2030
– Route of Administration Overview
– Oral Market Forecast, 2020-2030
– Injectable Market Forecast, 2020-2030
– Topical Forecast, 2020-2030
– Other Route of Administration Market Forecast, 2020-2030

– End-Use Revenue Forecast 2020-2030
– Hospitals Market Forecast, 2020-2030
– Research Lab Market Forecast, 2020-2030
– Clinics Market Forecast, 2020-2030
– Other End-Use Market Forecast, 2020-2030

– Understand the prospects for the 4 regional and the leading 12 national Atopic Dermatitis Drugs markets – where will the highest revenues and opportunities occur?
– Learn about the market potential for Atopic Dermatitis Drugs companies in the developed and developing countries, from 2019 onwards. You will see where and how opportunities exist with revealing individual market forecasts and analysis from 2020-2030 for 12 leading national markets by revenue, as well as segmented regional forecasts

– North America Atopic Dermatitis Drugs revenue forecast 2020-2030
– US Atopic Dermatitis Drugs revenue forecast 2020-2030
– Canada Atopic Dermatitis Drugs revenue forecast 2020-2030
– Mexico Atopic Dermatitis Drugs revenue forecast 2020-2030

– North America Atopic Dermatitis Drugs by Drug Type revenue forecast 2020-2030
– North America Atopic Dermatitis Drugs by Route of Administration revenue forecast 2020-2030
– North America Atopic Dermatitis Drugs by End-Use revenue forecast 2020-2030
– Asia Pacific Atopic Dermatitis Drugs revenue forecast 2020-2030
– China Atopic Dermatitis Drugs revenue forecast 2020-2030
– Japan Atopic Dermatitis Drugs revenue forecast 2020-2030
– India Atopic Dermatitis Drugs revenue forecast 2020-2030
– Australia Atopic Dermatitis Drugs revenue forecast 2020-2030
– Rest of Asia Pacific Atopic Dermatitis Drugs revenue forecast 2020-2030
– Asia Pacific Atopic Dermatitis Drugs by Drug Type revenue forecast 2020-2030
– Asia Pacific Atopic Dermatitis Drugs by Route of Administration revenue forecast 2020-2030
– Asia Pacific Atopic Dermatitis Drugs by End-Use revenue forecast 2020-2030
– European Atopic Dermatitis Drugs revenue forecast 2020-2030
– Germany Atopic Dermatitis Drugs revenue forecast 2020-2030
– UK Atopic Dermatitis Drugs revenue forecast 2020-2030
– France Atopic Dermatitis Drugs revenue forecast 2020-2030
– Italy Atopic Dermatitis Drugs revenue forecast 2020-2030
– Spain Atopic Dermatitis Drugs revenue forecast 2020-2030
– Rest of Europe Atopic Dermatitis Drugs revenue forecast 2020-2030
– European Atopic Dermatitis Drugs by Drug Type revenue forecast 2020-2030
– European Atopic Dermatitis Drugs by Route of Administration revenue forecast 2020-2030
– European Atopic Dermatitis Drugs by End-Use revenue forecast 2020-2030
– Rest of World Atopic Dermatitis Drugs revenue forecast 2020-2030
– Rest of World Atopic Dermatitis Drugs by Drug Type revenue forecast 2020-2030
– Rest of World Atopic Dermatitis Drugs by Route of Administration revenue forecast 2020-2030
– Rest of World Atopic Dermatitis Drugs by End-Use revenue forecast 2020-2030

– Explore the factors affecting Atopic Dermatitis Drugs product developers, and everyone within the value chain. Learn about the forces influencing market dynamics.
– Discover what the present and future outlook for business will be. Learn about the following business critical issues
– Research and development (R&D) strategy
– Technological issues and constraints.
– Competition from new product types
– Increasing specialisation by leading players
– Increasing industry consolidation.
– Advances in product quality
– Analysis of barriers to entry

– Identify who the leading companies are in the Atopic Dermatitis Drugs industry
– Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies: See where the expected gains will be. View visiongain’s assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of 10 leading Atopic Dermatitis Drugs companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and future outlook.

Leading Companies in the Global Atopic Dermatitis Drugs Market
Bayer
Sanofi
Regeneron
AbbVie
Dermira
Eli Lilly
Galderma
Mylan
LEO Pharma
Bausch Health

Discover Information found nowhere else in this independent assessment of the Atopic Dermatitis Drugs market
The Atopic Dermatitis Drugs Market Forecast 2020-2030: Forecasts and Analysis By Drug Type, By Route of Administration , By End-Use and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Atopic Dermatitis Drugs sector analysis. With the independent business intelligence found only in our work, you will discover where the prospects are for profit. In particular, our new research provides you with key strategic advantages: Our informed forecasts, independent and objective analysis, exclusive interviews and revealing company profiles will provide you with that necessary edge, allowing you to gain ground over your competitors.

With this report you are less likely to fall behind in knowledge or miss crucial business opportunities. You will save time and receive recognition for your market insight. See how you this report could benefit and enhance your research, analysis, company presentations and ultimately your individual business decisions and your company’s prospects.

What makes this report unique?
Visiongain’s research methodology involves an exclusive blend of primary and secondary sources providing informed analysis. This methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments. The report therefore presents an ideal balance of qualitative analysis combined with extensive quantitative data including global, submarket and regional markets forecasts from 2020-2030

How the Atopic Dermatitis Drugs Market Forecast 2020-2030: Forecasts and Analysis By Drug Type, By Route of Administration , By End-Use and and Geography, with Profiles of Leading Companies report can benefit you
Visiongain’s report is for anyone requiring analysis of the Atopic Dermatitis Drugs market. You will discover market forecasts, technological trends, predictions and expert opinion providing you with independent analysis derived from our extensive primary and secondary research. Only by purchasing this report will you receive this critical business intelligence revealing where revenue growth is likely and where the lucrative potential market prospects are. Don’t miss this key opportunity to gain a competitive advantage.

Avoid falling behind your competitors, overlooking critical business opportunities or losing industry influence. In our new report you will discover forecasts from 2020-2030 at the global, submarket, and national level. The report also assesses technologies, competitive forces and expected product pipeline developments. Read on to discover the prospects for the Atopic Dermatitis Drugs sector and find out what its future market prospects are.

If you buy our report today your knowledge will stay one step ahead of your competitors. Discover how our report could benefit your research, analyses and strategic decisions, saving you time. To gain an understanding of how to tap into the potential of this market and stay one step ahead of the competition you must order now our report the Atopic Dermatitis Drugs Market Forecast 2020-2030: Forecasts and Analysis By Drug Type, By Route of Administration , By End-Use and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Atopic Dermatitis Drugs sector analysis. Avoid missing out – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Report Overview

1.1 Global Atopic Dermatitis Drugs Market Definition

1.2 Global Atopic Dermatitis Drugs Market Overview

1.3 Global Atopic Dermatitis Drugs Market Segmentation

1.4 Research Scope of Atopic Dermatitis Drugs in the Industry

1.5 Why You Should Read This Report

1.6 How This Report Delivers

1.7 Key Questions Answered by This Analytical Report

1.8 Methodology

1.8.1 Secondary Research

1.8.2 Market Evaluation & Forecasting Methodology

1.9 Frequently Asked Questions (FAQ)

1.10 Associated Visiongain Reports

1.11 About Visiongain

2. Introduction to Atopic Dermatitis Drugs Systems Market

2.1 Market Definition

2.2 Industry Structure

2.3 Industry Outlook

2.4 Current Status & Trends

2.4.1 Recent introduction of biologics and micro molecules such as Dupixent and Eucrisais

2.4.2 Launch of more biologics & tiny molecules, premium-priced medicines to replace conventional first-line and second-line therapies

2.4.3 High therapy costs are one of the main roadblocks

2.4.4 Application of treatment guidelines for atopic dermatitis is difficult

2.5 Product Penetration & growth prospect Analysis

2.5.1 Advanced manufacturing process innovation

3. Global Atopic Dermatitis Drugs Market Analysis

3.1 PEST Analysis of the Atopic Dermatitis Drugs Market

3.2 Expert Opinion

3.2.1 Primary Correspondents

3.3 Market Outlook

3.4 Drivers & Restraints

3.5 Dominant Region/Country

3.6 Market Scenario

3.7 Overall Growth Rate, Globally

3.8 SWOT Analysis of the Atopic Dermatitis Drugs Market

3.8.1 Strengths

3.8.2 Weaknesses

3.8.3 Opportunities

3.8.4 Threats

3.9 Porter’s Five Forces Analysis

3.9.1 Competitive Rivalry

3.9.1.1 Powerful Competitive Strategy

3.9.1.2 Firm Concentration Ratio

3.9.1.3 Degree Of Transparency

3.9.2 Supplier Power

3.9.2.1 Supplier Switching Costs Relative To Firm Switching Costs

3.9.2.2 Supplier Concentration To Firm Concentration Ratio

3.9.2.3 Degree Of Differentiation Of Inputs

3.9.3 Buyer Power

3.9.3.1 Degree Of Dependency Upon Existing Channels Of Distribution

3.9.3.2 Buyer Switching Costs Relative To Firm Switching Costs

3.9.3.3 Buyer Concentration To Firm Concentration Ratio

3.9.4 Threat Of Substitute

3.9.4.1 Buyer Propensity To Substitute

3.9.4.2 Relative Price Performance Of Substitute

3.9.4.3 Perceived Level Of Product Differentiation

3..9.5 Threat Of New Entrant

3.9.5.1 Economies Of Scale

3.9.5.2 Switching Costs Or Sunk Costs

3.9.5.3 Industry Profitability (Market CAGR)

4. Atopic Dermatitis Drugs: Global Market Analysis by Segments

4.1 Global Atopic Dermatitis Drugs Market Forecast, by Drug Type 2020-2030

4.1.1 Drug Type Overview

4.1.2 Anti-inflammatory agents Market Forecast, 2020-2030

4.1.3 Antihistamines Market Forecast, 2020-2030

4.1.4 Immunosuppressant Market Forecast, 2020-2030

4.1.5 Interleukin Inhibitors Market Forecast, 2020-2030

4.1.6 Topical Phosphodiesterase (PDE-4) Market Forecast, 2020-2030

4.1.7 Other Drug Type Market Forecast, 2020-2030

4.2 Global Atopic Dermatitis Drugs Market Forecast, by Route of Administration 2020-2030

4.2.1 Route of Administration Overview

4.2.2 Oral Market Forecast, 2020-2030

4.2.3 Injectable Market Forecast, 2020-2030

4.2.4 Topical Forecast, 2020-2030

4.2.5 Other Route of Administration Market Forecast, 2020-2030

4.3 Global Atopic Dermatitis Drugs Market Forecast, by End-Use 2020-2030

4.3.1 End-Use Overview

4.3.2 Hospitals Market Forecast, 2020-2030

4.3.3 Research Lab Market Forecast, 2020-2030

4.3.4 Clinics Market Forecast, 2020-2030

4.3.5 Other End-Use Market Forecast, 2020-2030

5. Leading Regions in Atopic Dermatitis Drugs Market 2020-2030

5.1 Regional Overview

5.1.1 North America

5.1.2 Europe

5.1.3 Asia Pacific

5.1.4 LAMEA

5.1.5 Leading Countries/ Regions

5.2 North America Atopic Dermatitis Drugs Market Forecast, 2020-2030

5.2.1 North America Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

5.2.2 North America Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030

5.2.3 North America Atopic Dermatitis Drugs Submarket, By End-Use Forecast 2020-2030

5.2.4 North America Atopic Dermatitis Drugs Submarket, By Country Forecast 2020-2030

5.2.4.1 U.S. Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.2.4.2 Canada Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.2.4.3 Mexico Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.3 Europe Atopic Dermatitis Drugs Market Forecast, 2020-2030

5.3.1 Europe Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

5.3.2 Europe Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030

5.3.3 Europe Atopic Dermatitis Drugs Submarket, By End-Use Forecast 2020-2030

5.3.4 Europe Atopic Dermatitis Drugs Submarket, By Country Forecast 2020-2030

5.3.4.1 U.K. Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.3.4.2 Germany Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.3.4.3 France Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.3.4.4 Italy Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.3.4.5 Spain Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.3.4.6 The Netherlands Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.3.4.7 Rest of Europe Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.4 Asia-Pacific Atopic Dermatitis Drugs Market Forecast, 2020-2030

5.4.1 Asia-Pacific Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

5.4.2 Asia-Pacific Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030

5.4.3 Asia-Pacific Atopic Dermatitis Drugs Submarket, By End-Use Forecast 2020-2030

5.4.4 Asia-Pacific Atopic Dermatitis Drugs Submarket, By Country Forecast 2020-2030

5.4.4.1 China Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.4.4.2 India Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.4.4.3 Japan Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.4.4.4 Korea Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.4.4.5 Indonesia Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.4.4.6 Australia Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.4.4.7 Rest of Asia-Pacific Atopic Dermatitis Drugs Market, Forecast 2020-2030

5.5 Rest of World Atopic Dermatitis Drugs Market Forecast, 2020-2030

5.5.1 Rest of World Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

5.5.2 Rest of World Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030

5.5.3 Rest of World Atopic Dermatitis Drugs Submarket, By End-Use Forecast 2020-2030

6. Leading Companies in The Atopic Dermatitis Drugs Market

6.1 Bayer

6.1.1 Bayer Overview

6.1.2 Analysis of Bayer Products and Services

6.1.3 Bayer Primary Market Competitors 2019

6.1.4 Bayer Key Developments

6.2 Sanofi

6.2.1 Sanofi Company Overview

6.2.2 Analysis of Sanofi Products and Services

6.2.3 Sanofi Primary Market Competitors 2019

6.2.4 Sanofi Key Developments

6.3 Regeneron

6.3.1 Regeneron Company Overview

6.3.2 Analysis of Regeneron Products and Services

6.3.3 Regeneron Primary Market Competitors 2019

6.3.4 Regeneron Key Developments

6.4 AbbVie

6.4.1 AbbVie Company Overview

6.4.2 Analysis of AbbVie Products and Services

6.4.3 AbbVie Primary Market Competitors 2019

6.4.4 AbbVie Key Developments

6.5 Dermira

6.5.1 Dermira Company Overview

6.5.2 Analysis of Dermira Products and Services

6.5.3 Dermira Primary Market Competitors 2019

6.5.4 Dermira Key Developments

6.6 Eli Lilly

6.6.1 Eli Lilly Company Overview

6.6.2 Analysis of Eli Lilly Products and Services

6.6.3 Eli Lilly Primary Market Competitors 2019

6.6.4 Eli Lilly Key Developments

6.7 Galderma

6.6.1 Galderma Company Overview

6.6.2 Analysis of Galderma Products and Services

6.6.3 Galderma Primary Market Competitors 2019

6.6.4 Galderma Key Developments

6.8 Mylan

6.8.1 Mylan Company Overview

6.8.2 Analysis of Mylan Products and Services

6.8.3 Mylan Primary Market Competitors 2019

6.8.4 Mylan Key Developments

6.9 LEO Pharma

6.9.1 LEO Pharma Company Overview

6.9.2 Analysis of LEO Pharma Products and Services

6.9.3 LEO Pharma Primary Market Competitors 2019

6.9.4 LEO Pharma Key Developments

6.10 Incyte

6.10.1 Incyte Company Overview

6.10.2 Analysis of Incyte Products and Services

6.10.3 Incyte Primary Market Competitors 2019

6.10.4 Incyte Key Developments

7. Conclusions and Recommendations

7.1. Key Research Findings

7.2. Conclusion by Geography

7.3. Conclusion by Solution Type

7.4. Strategic Recommendations

8. Glossary

Associated Visiongain Reports

Visiongain Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain Report Evaluation Form

List of Figures

Figure 1.1 Global Atopic Dermatitis Drugs Market Segmentation

Figure 2.1 Atopic Dermatitis Drugs Value Chain Analysis

Figure 3.1 Atopic Dermatitis Drugs Supply-Demand Analysis

Figure 4.1 Global Atopic Dermatitis Drugs Forecast 2020-2030 ($billion, AGR %)

Figure 4.2 Global Atopic Dermatitis Drugs Market Forecast 2020-2030

Figure 4.3 Global Atopic Dermatitis Drugs Submarket Forecast by 2020-2030 ($ billion)

Figure 4.4 Global Atopic Dermatitis Drugs Market By Drug Type Share Forecast 2019, 2025, 2029 (% Share)

Figure 4.19 Global Atopic Dermatitis Drugs by Submarket By Drug Type Forecast 2020-2030 ($ million)

Figure 4.20 Global Atopic Dermatitis Drugs Market, by Share Forecast 2019, 2025, 2029 (% Share)

Figure 4.21 Atopic Dermatitis Drugs Market, By Route of Administration Forecast 2020-2030 ($billion, AGR%)

Figure 4.23 Atopic Dermatitis Drugs Market, By End-Use System Forecast 2020-2030 ($billion, AGR%)

Figure 4.25 Atopic Dermatitis Drugs Market, By Drug Type Forecast 2020-2030 ($billion, AGR%)

Figure 4.27 Atopic Dermatitis Drugs Market, By Route of Administration Forecast 2020-2030 ($billion, AGR%)

Figure 5.1 Regional/Country Atopic Dermatitis Drugs Market, by 2020-2030

Figure 5.3 Leading Country/Regional Atopic Dermatitis Drugs Market Share, by 2020

Figure 5.4 Leading Country/Regional Atopic Dermatitis Drugs Market Share, by 2025

Figure 5.5 Leading Country/Regional Atopic Dermatitis Drugs Market Share, by 2030

Figure 5.6 Europe Atopic Dermatitis Drugs Market Forecast 2020-2030 ($billion, AGR%)

Figure 5.7 Europe Atopic Dermatitis Drugs Market, by Forecast 2020-2030

Figure 5.8 Europe Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

Figure 5.9 Europe Atopic Dermatitis Drugs Submarket , By Route of Administration Forecast 2020-2030

Figure 5.10 Europe Atopic Dermatitis Drugs Submarket , By Country Forecast 2020-2030

Figure 5.11 Europe Atopic Dermatitis Drugs Submarket , By End-Use 2020-2030 ($billion, AGR%)

Figure 5.10 North America Atopic Dermatitis Drugs Market Forecast 2020-2030 ($billion, AGR%)

Figure 5.11 North America Atopic Dermatitis Drugs Market, by Forecast 2020-2030

Figure 5.12 North America Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

Figure 5.13 North America Atopic Dermatitis Drugs Submarket , By Route of Administration Forecast 2020-2030

Figure 5.14 North America Atopic Dermatitis Drugs Submarket , By End-Use Forecast 2020-2030

Figure 5.13 North America Atopic Dermatitis Drugs Submarket , By Country Forecast 2020-2030

Figure 5.14 Asia-Pacific Atopic Dermatitis Drugs Market Forecast 2020-2030 ($billion , AGR%)

Figure 5.15 Asia-Pacific Atopic Dermatitis Drugs Market, by Forecast 2020-2030

Figure 5.16 Asia-Pacific Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

Figure 5.17 Asia-Pacific Atopic Dermatitis Drugs Submarket , By Country Forecast 2020-2030

Figure 5.17 Asia-Pacific Atopic Dermatitis Drugs Submarket , By End-Use Forecast 2020-2030

Figure 5.18 Rest of World Atopic Dermatitis Drugs Market Forecast 2020-2030 ($billion, AGR%)

Figure 5.19 Rest of World Atopic Dermatitis Drugs Market, by Forecast 2020-2030

Figure 5.20 Rest of World Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030

Figure 5.21 Rest of World Atopic Dermatitis Drugs Submarket , By Route of Administration Forecast 2020-2030

Figure 5.21 Rest of World Atopic Dermatitis Drugs Submarket , By End-Use Forecast 2020-2030

Figure 6.1 3M Total Company Sales 2013-2019 (US$ million, AGR %)

Figure 6.2 Sanofi Total Company Sales 2013-2019 (US$ million, AGR %)

Figure 6.3 Regeneron Total Company Sales 2013-2019 (US$ Bn, AGR %)

Figure 6.6 AbbVie Company Sales 2013-2019 (US$ bn, AGR %)

Figure 6.7 AbbVie Revenue % Share, by End-Use Segment, 2019

Figure 6.8 AbbVie Revenue % Share, by Geographical Trade, 2019

Figure 6.9 AbbVie Revenue % Share, by Business Segment, 2019

Figure 6.10 Dermira Revenue % Share, by Geographic Segment, 2019

Figure 6.11 Eli Lilly Company Total Company Sales 2013-2019 (US$ million, AGR %)

Figure 6.12 Galderma Total Company Sales 2013-2019 (US$ million, AGR %)

Figure 6.13 Galderma Revenue % Share, by Regional Segment, 2019

Figure 6.14 Mylan Total Company Sales 2013-2019 (US$ million, AGR %)

Figure 6.15 Mylan Revenue % Share, by Regional Segment, 2019

Figure 6.16 Mylan Revenue % Share, by Business Segment, 2019

Figure 6.17 LEO Pharma Total Company Sales 2013-2019 (US$ bn, AGR %)

Figure 6.18 Incyte Total Company Revenue 2013-2019 (US$ bn, AGR %)

Figure 6.19 Incyte Company Sales 2014-2019 (US$ bn, AGR %)

Figure 6.20 Incyte Revenue % Share, by Business Segment, 2019

List of Tables

Table 1.0 Research Scope

Table 4.1 Global Atopic Dermatitis Drugs Market Forecast 2020-2030 ($Bn, AGR %, CAGR %)

Table 4.2 Global Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)

Table 4.3 Global Atopic Dermatitis Drugs Submarket, By End-Use Forecast 2020-2030 ($billion, AGR %)

Table 5.1 Global Atopic Dermatitis Drugs Market, by Country/Region Forecast 2020-2030 ($billion, AGR %)

Table 5.3 Europe Atopic Dermatitis Drugs Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)

Table 5.4 Europe Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)

Table 5.5 Europe Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030 ($billion, AGR %)

Table 5.6 North America Atopic Dermatitis Drugs Market Submarket, By End-Use Forecast 2020-2030 ($billion, , AGR %, CAGR %)

Table 5.7 North America Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)

Table 5.8 North America Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030 ($billion, AGR %)

Table 5.9 Asia-Pacific Atopic Dermatitis Drugs Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)

Table 5.10 Asia-Pacific Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)

Table 5.11 Asia-Pacific Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030 ($billion, AGR %)

Table 5.12 Rest of World Atopic Dermatitis Drugs Market Submarket, By End-Use Forecast 2020-2030 ($billion, , AGR %, CAGR %)

Table 5.13 Rest of World Atopic Dermatitis Drugs Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)

Table 5.14 Rest of World Atopic Dermatitis Drugs Submarket, By Route of Administration Forecast 2020-2030 ($billion, AGR %)

Table 6.1 3M Profile 2019 (Market Entry, Public/Private, Headquarters, Geography, Key Market, Listed on, Products/Services

Table 6.2 3M Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.3 3M Products and Services (Product/Service, Segment)

Table 6.4 3M Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.5 3M Total Company Recent Development 2015-2019

Table 6.6 Sanofi Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.7 Sanofi Products and Services (Product/Service, Segment)

Table 6.8 Sanofi Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.9 Sanofi Total Company Recent Development 2015-2019

Table 6.10 Regeneron Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.11 Regeneron Products and Services (Product/Service, Segment)

Table 6.12 Regeneron Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.13 Regeneron Total Company Recent Development 2015-2019

Table 6.14 AbbVie Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.15 AbbVie Products and Services (Product/Service, Segment)

Table 6.16 AbbVie Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.17 AbbVie Total Company Recent Development 2015-2019

Table 6.18 Dermira Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.19 Dermira Products and Services (Product/Service, Segment)

Table 6.20 Dermira Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.21 Dermira Total Company Recent Development 2015-2019

Table 6.22 Eli Lilly Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.23 Eli Lilly Products and Services (Product/Service, Segment)

Table 6.24 Eli Lilly Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.25 Eli Lilly Total Company Recent Development 2015-2019

Table 6.26 Galderma Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.27 Galderma Products and Services (Product/Service, Segment)

Table 6.28 Galderma Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.29 Galderma Total Company Recent Development 2015-2019

Table 6.30 Mylan Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.31 Mylan Products and Services (Product/Service, Segment)

Table 6.32 Mylan Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.33 Mylan Total Company Recent Development 2015-2019

Table 6.34 LEO Pharma Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.35 LEO Pharma Products and Services (Product/Service, Segment)

Table 6.36 LEO Pharma Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.37 LEO Pharma Total Company Recent Development 2015-2019

Table 6.38 Incyte Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)

Table 6.39 Incyte Products and Services (Product/Service, Segment)

Table 6.40 Incyte Total Company Sales 2015-2019 (US$billion, AGR %)

Table 6.41 Incyte Total Company Recent Development 2015-2019

Bayer

Sanofi

Regeneron

AbbVie

Dermira

Eli Lilly

Galderma

Mylan

LEO Pharma

Incyte

Bausch Health

Allergan Plc.

Galderma S.A.

Pfizer Inc.

Meda Pharmaceuticals

Bristol-Myers Squibb

Novartis International AG

Anacor Pharmaceuticals Inc.

Valeant Pharmaceuticals International Inc

Regeneron Pharmaceuticals Inc.

Sanofi S.A.

Astellas Pharma Inc.

Connectics Corporation

Fujisawa Healthcare

Encore Dermatology Inc.

Velite Pharmaceuticals

Biofrontera AG

Hoffmann-La Roche AG

GlaxoSmithKline plc.

AsteraZeneca

Download sample pages

Complete the form below to download your free sample pages for Atopic Dermatitis Drugs Market Forecast 2020-2030

Download sample pages

Complete the form below to download your free sample pages for Atopic Dermatitis Drugs Market Forecast 2020-2030

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

READ

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

READ

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

READ

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

READ

Industries > Pharma > Atopic Dermatitis Drugs Market Forecast 2020-2030

Back to Pharma Reports

Atopic Dermatitis Drugs Market Forecast 2020-2030

Atopic Dermatitis Drugs Market Forecast 2020-2030: Forecasts and Analysis by Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report by Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics) and Geography with Profiles of Leading Companies

Download sample pages

Related reports

Allergic Rhinitis Drugs Market Report 2020-2030

Antibiotic Resistance Market Report 2019-2029

Migraine Drugs Market Analysis Report 2020-2030

Myeloproliferative Disorders Drugs Report 2020-2030

Generic Drugs Market Report 2020-2030

Global Anti-obesity Drugs Market Forecast 2020-2030

Antibacterial Drugs Market Report 2020-2030

Myelodysplastic Syndrome (MDS) Drugs Report 2020-2030

Dermatological Drugs Market Forecast 2020-2030

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

Our Clients